APCCC 2024 | The impact of repeat next generation sequencing in metastatic prostate cancer

Andrew Armstrong, MD, Duke University, Durham, NC, discusses findings from a recent study published in JCO Precision Oncology on the benefits of repeat next generation sequencing (NGS) in metastatic prostate cancer. The PROMIS consortium study revealed that re-testing in the castration-resistant setting can identify new actionable genetic alterations, such as BRCA1/2 mutations and MSI-high status, which were not detected during initial testing. These findings suggest that repeat molecular testing can uncover additional treatment options, improving patient outcomes. This interview took place at the 2024 Advanced Prostate Cancer Consensus Conference (APCCC) in Lugano, Switzerland.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.